88 related articles for article (PubMed ID: 16365604)
21. Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Recchia F; Candeloro G; Necozione S; Accorsi P; Recchia CO; Tombolini V; Rea S
Anticancer Res; 2010 Jan; 30(1):209-15. PubMed ID: 20150637
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.
Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E
Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742
[TBL] [Abstract][Full Text] [Related]
23. Maintenance immunotherapy in metastatic breast cancer.
Recchia F; Sica G; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
Oncol Rep; 2008 Nov; 20(5):1173-9. PubMed ID: 18949418
[TBL] [Abstract][Full Text] [Related]
24. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
25. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
26. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Herbst RS
Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
[TBL] [Abstract][Full Text] [Related]
27. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
Pallaud C; Reck M; Juhasz E; Szima B; Yu CJ; Burdaeva O; Orlov S; Hilton M; Archer V; Mok T
Lung Cancer; 2014 Oct; 86(1):67-72. PubMed ID: 25154982
[TBL] [Abstract][Full Text] [Related]
28. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
29. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
31. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
[TBL] [Abstract][Full Text] [Related]
32. Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Li J; Hu YM; Du YJ; Zhu LR; Qian H; Wu Y; Shi WL
BMC Cancer; 2014 Nov; 14():848. PubMed ID: 25410981
[TBL] [Abstract][Full Text] [Related]
33. Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Jia Y; Li X; Zhao C; Jiang T; Zhao S; Zhang L; Liu X; Shi J; Qiao M; Luo J; Liu S; Han R; Chen X; Zhou C
Lung Cancer; 2018 Nov; 125():22-28. PubMed ID: 30429024
[TBL] [Abstract][Full Text] [Related]
34. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586).
Tester WJ; Kim KM; Krigel RL; Bonomi PD; Glick JH; Asbury RF; Kirkwood JM; Blum RH; Schiller JH
Lung Cancer; 1999 Sep; 25(3):199-206. PubMed ID: 10512131
[TBL] [Abstract][Full Text] [Related]
35. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
[TBL] [Abstract][Full Text] [Related]
36. Carboplatin, vindesine, 5-fluorouracil-leucovorin and 13-cis retinoic acid in the treatment of advanced non-small cell lung cancer. A phase II study.
Recchia F; De Filippis S; Pompili PL; Rosselli M; Saggio G; Ciorra A; Piccinini M; Rea S
Clin Ter; 1999; 150(4):269-74. PubMed ID: 10605163
[TBL] [Abstract][Full Text] [Related]
37. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
[TBL] [Abstract][Full Text] [Related]
38. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
Wu F; Zhang S; Xiong A; Gao G; Li W; Cai W; Su C; Chen X; Zhou F; Zhao J; Ren S; Zhou C
Clin Lung Cancer; 2018 Nov; 19(6):e831-e842. PubMed ID: 30026059
[TBL] [Abstract][Full Text] [Related]
39. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
40. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
Dudek AZ; Mahaseth H
Cancer Invest; 2005; 23(3):193-200. PubMed ID: 15945504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]